Covestro Makrolon polycarbonate utilised for wound healing device

Denver-based Vaporox developed a medical device for healing chronic wounds that do not respond to conventional wound treatment. The vaporiser component of the medical device primarily utilises Makrolon 2458 polycarbonate from Covestro.

The VHT-200 (Vaporous Hyperoxia Therapy) system, which received US Food and Drug Administration (FDA) clearance, features a unique combination of elements that accelerate healing—ultrasonic vapour and concentrated oxygen. According to Vaporox, the patented delivery system for these elements promotes revascularisation and tissue growth. The treatment is intended for administration in clinics and physicians’ offices.

“Vaporox is committed to a world where all wounds heal,” said Chase Huskey, marketing manager, Vaporox. “Today, wound care is one of the most under-served markets in the medical industry, but this development is truly life-changing for patients and a huge step forward for this market.” 

Covestro was involved throughout the device’s development, supplying prototype quantities of its material, and documentation required by the FDA.

Makrolon 2458 polycarbonate is a low-viscosity, injection moulding medical grade that features easy release from the mould. It is suitable for Ethylene Oxide (EtO) and steam sterilisation and is biocompatible according to many ISO 10993-1 test requirements.

“For decades, the healthcare market has relied on our proven portfolio of medical grade Makrolon polycarbonates, complemented by customised technical expertise,” said Mark Nichols, healthcare key account manager, Covestro. “Our work with Vaporox demonstrates the value of collaboration as our customers develop and bring truly innovative, game-changing technology to market."

Attendees at MD&M West can visit the Covestro booth (#2221).